NASDAQ:ATRS - Antares Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.26 -0.11 (-3.26 %) (As of 09/23/2018 04:00 PM ET)Previous Close$3.26Today's Range$3.24 - $3.405052-Week Range$1.58 - $4.09Volume2.54 million shsAverage Volume1.05 million shsMarket Capitalization$513.24 millionP/E RatioN/ADividend YieldN/ABeta0.34 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc., as well as a development agreement with Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey. Receive ATRS News and Ratings via Email Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical SymbolNASDAQ:ATRS CUSIP03664210 Webwww.antarespharma.com Phone609-359-3020 Debt Debt-to-Equity Ratio1.01 Current Ratio2.33 Quick Ratio1.89 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$54.51 million Price / Sales9.42 Cash FlowN/A Price / CashN/A Book Value$0.21 per share Price / Book15.52 Profitability EPS (Most Recent Fiscal Year)($0.11) Net Income$-16,740,000.00 Net Margins-35.53% Return on Equity-64.96% Return on Assets-26.68% Miscellaneous Employees111 Outstanding Shares157,440,000Market Cap$513.24 million Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions What is Antares Pharma's stock symbol? Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS." How were Antares Pharma's earnings last quarter? Antares Pharma Inc (NASDAQ:ATRS) released its earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.01. The specialty pharmaceutical company had revenue of $14.16 million for the quarter, compared to analyst estimates of $13.70 million. Antares Pharma had a negative return on equity of 64.96% and a negative net margin of 35.53%. View Antares Pharma's Earnings History. When is Antares Pharma's next earnings date? Antares Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Antares Pharma. What price target have analysts set for ATRS? 2 brokers have issued 1 year price objectives for Antares Pharma's stock. Their forecasts range from $4.00 to $5.00. On average, they anticipate Antares Pharma's stock price to reach $4.50 in the next year. This suggests a possible upside of 38.0% from the stock's current price. View Analyst Price Targets for Antares Pharma. What is the consensus analysts' recommendation for Antares Pharma? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma. Who are some of Antares Pharma's key competitors? Some companies that are related to Antares Pharma include Nevro (NVRO), Mazor Robotics (MZOR), Luminex (LMNX), Cryolife (CRY), AtriCure (ATRC), Cardiovascular Systems (CSII), Atrion (ATRI), K2M Group (KTWO), Tactile Systems Technology (TCMD), Orthofix Medical (OFIX), Cerus (CERS), SurModics (SRDX), OraSure Technologies (OSUR), Intersect ENT (XENT) and AngioDynamics (ANGO). Who are Antares Pharma's key executives? Antares Pharma's management team includes the folowing people: Mr. Robert F. Apple, CEO, Pres & Director (Age 52)Mr. Fred M. Powell, Exec. VP & CFO (Age 57)Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51)Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. and Corp. Controller (Age 55)Edward Kessig, VP of Sales Who are Antares Pharma's major shareholders? Antares Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.25%), FMR LLC (2.31%), Mycio Wealth Partners LLC (1.55%), JW Asset Management LLC (1.16%), Northern Trust Corp (1.09%) and Russell Investments Group Ltd. (0.72%). Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma. Which major investors are selling Antares Pharma stock? ATRS stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Bank of New York Mellon Corp and Bank of New York Mellon Corp. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma. Which major investors are buying Antares Pharma stock? ATRS stock was bought by a variety of institutional investors in the last quarter, including Mycio Wealth Partners LLC, FMR LLC, BlackRock Inc., United Services Automobile Association, Russell Investments Group Ltd., Northern Trust Corp, JW Asset Management LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Antares Pharma. How do I buy shares of Antares Pharma? Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Antares Pharma's stock price today? One share of ATRS stock can currently be purchased for approximately $3.26. How big of a company is Antares Pharma? Antares Pharma has a market capitalization of $513.24 million and generates $54.51 million in revenue each year. The specialty pharmaceutical company earns $-16,740,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Antares Pharma employs 111 workers across the globe. What is Antares Pharma's official website? The official website for Antares Pharma is http://www.antarespharma.com. How can I contact Antares Pharma? Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected] MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 268 (Vote Outperform)Underperform Votes: 192 (Vote Underperform)Total Votes: 460MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/23/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?